Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Lymphovascular invasion is an independent predictor of oncological outcomes in patients with lymph node-negative urothelial bladder cancer treated by radical cystectomy: a multicentre validation trial.

Bolenz C, Herrmann E, Bastian PJ, Michel MS, Wülfing C, Tiemann A, Buchner A, Stief CG, Fritsche HM, Burger M, Wieland WF, Höfner T, Haferkamp A, Hohenfellner M, Müller SC, Ströbel P, Trojan L.

BJU Int. 2010 Aug;106(4):493-9. doi: 10.1111/j.1464-410X.2009.09166.x. Epub 2010 Jan 8.

2.

Developing a multidisciplinary prospective melanoma biospecimen repository to advance translational research.

Wich LG, Hamilton HK, Shapiro RL, Pavlick A, Berman RS, Polsky D, Goldberg JD, Hernando E, Manga P, Krogsgaard M, Kamino H, Darvishian F, Lee P, Orlow SJ, Ostrer H, Bhardwaj N, Osman I.

Am J Transl Res. 2009;1(1):35-43. Epub 2009 Jan 1.

3.

Final version of 2009 AJCC melanoma staging and classification.

Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sober AJ, Sondak VK.

J Clin Oncol. 2009 Dec 20;27(36):6199-206. doi: 10.1200/JCO.2009.23.4799. Epub 2009 Nov 16.

4.

Multivariate analysis of clinicopathological factors influencing survival following esophagectomy for cancer.

Mirnezami R, Rohatgi A, Sutcliffe RP, Hamouda A, Chandrakumaran K, Botha A, Mason RC.

Int J Surg. 2010;8(1):58-63. doi: 10.1016/j.ijsu.2009.11.001. Epub 2009 Nov 6.

5.

Lymphatic invasion detected by D2-40/S-100 dual immunohistochemistry does not predict sentinel lymph node status in melanoma.

Petitt M, Allison A, Shimoni T, Uchida T, Raimer S, Kelly B.

J Am Acad Dermatol. 2009 Nov;61(5):819-28. doi: 10.1016/j.jaad.2009.04.026.

PMID:
19836642
6.

Immunohistochemical detection of lymphovascular invasion with D2-40 in melanoma correlates with sentinel lymph node status, metastasis and survival.

Petersson F, Diwan AH, Ivan D, Gershenwald JE, Johnson MM, Harrell R, Prieto VG.

J Cutan Pathol. 2009 Nov;36(11):1157-63. doi: 10.1111/j.1600-0560.2008.01242.x. Epub 2009 Feb 5.

PMID:
19222695
7.

Lymphatic invasion in cutaneous melanoma is associated with sentinel lymph node metastasis.

Doeden K, Ma Z, Narasimhan B, Swetter SM, Detmar M, Dadras SS.

J Cutan Pathol. 2009 Jul;36(7):772-80. doi: 10.1111/j.1600-0560.2008.01166.x. Epub 2008 Nov 5.

PMID:
19032379
8.

Lymphatic invasion revealed by multispectral imaging is common in primary melanomas and associates with prognosis.

Xu X, Gimotty PA, Guerry D, Karakousis G, Van Belle P, Liang H, Montone K, Pasha T, Ming ME, Acs G, Feldman M, Barth S, Hammond R, Elenitsas R, Zhang PJ, Elder DE.

Hum Pathol. 2008 Jun;39(6):901-9. doi: 10.1016/j.humpath.2007.10.017. Epub 2008 Apr 28.

9.

Lymphatic invasion identified by monoclonal antibody D2-40, younger age, and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma.

Niakosari F, Kahn HJ, McCready D, Ghazarian D, Rotstein LE, Marks A, Kiss A, From L.

Arch Dermatol. 2008 Apr;144(4):462-7. doi: 10.1001/archderm.144.4.462.

PMID:
18427039
10.
11.

First--select the target: better choice of adjuvant treatments for breast cancer patients.

Goldhirsch A, Coates AS, Gelber RD, Glick JH, Thürlimann B, Senn HJ; St Gallen Expert Panel Members.

Ann Oncol. 2006 Dec;17(12):1772-6. Epub 2006 Oct 27.

PMID:
17071934
12.

Distinguishing blood and lymph vessel invasion in breast cancer: a prospective immunohistochemical study.

Van den Eynden GG, Van der Auwera I, Van Laere SJ, Colpaert CG, van Dam P, Dirix LY, Vermeulen PB, Van Marck EA.

Br J Cancer. 2006 Jun 5;94(11):1643-9.

13.

Tumour lymphangiogenesis is a possible predictor of sentinel lymph node status in cutaneous melanoma: a case-control study.

Massi D, Puig S, Franchi A, Malvehy J, Vidal-Sicart S, González-Cao M, Baroni G, Ketabchi S, Palou J, Santucci M.

J Clin Pathol. 2006 Feb;59(2):166-73.

14.

The use of LYVE-1 antibody for detecting lymphatic involvement in patients with malignant melanoma of known sentinel node status.

Sahni D, Robson A, Orchard G, Szydlo R, Evans AV, Russell-Jones R.

J Clin Pathol. 2005 Jul;58(7):715-21.

15.
16.

Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes.

Dadras SS, Lange-Asschenfeldt B, Velasco P, Nguyen L, Vora A, Muzikansky A, Jahnke K, Hauschild A, Hirakawa S, Mihm MC, Detmar M.

Mod Pathol. 2005 Sep;18(9):1232-42.

17.

Lymphatic density and metastatic spread in human malignant melanoma.

Shields JD, Borsetti M, Rigby H, Harper SJ, Mortimer PS, Levick JR, Orlando A, Bates DO.

Br J Cancer. 2004 Feb 9;90(3):693-700.

18.
19.

Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival.

Dadras SS, Paul T, Bertoncini J, Brown LF, Muzikansky A, Jackson DG, Ellwanger U, Garbe C, Mihm MC, Detmar M.

Am J Pathol. 2003 Jun;162(6):1951-60.

20.

A new monoclonal antibody, D2-40, for detection of lymphatic invasion in primary tumors.

Kahn HJ, Marks A.

Lab Invest. 2002 Sep;82(9):1255-7. No abstract available.

PMID:
12218087

Supplemental Content

Support Center